Harbour Trust & Investment Management Co Sells 3,780 Shares of Johnson & Johnson (NYSE:JNJ)

Harbour Trust & Investment Management Co trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 6.8% during the 1st quarter, Holdings Channel reports. The firm owned 52,197 shares of the company’s stock after selling 3,780 shares during the quarter. Johnson & Johnson comprises approximately 1.0% of Harbour Trust & Investment Management Co’s portfolio, making the stock its 28th biggest holding. Harbour Trust & Investment Management Co’s holdings in Johnson & Johnson were worth $8,257,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of JNJ. Centennial Wealth Advisory LLC grew its position in Johnson & Johnson by 6.2% during the first quarter. Centennial Wealth Advisory LLC now owns 1,635 shares of the company’s stock valued at $259,000 after acquiring an additional 95 shares during the last quarter. America First Investment Advisors LLC grew its position in Johnson & Johnson by 3.4% during the first quarter. America First Investment Advisors LLC now owns 111,825 shares of the company’s stock valued at $17,690,000 after acquiring an additional 3,692 shares during the last quarter. HF Advisory Group LLC grew its position in Johnson & Johnson by 5.5% during the first quarter. HF Advisory Group LLC now owns 4,807 shares of the company’s stock valued at $761,000 after acquiring an additional 252 shares during the last quarter. PFG Investments LLC grew its position in Johnson & Johnson by 431.2% during the first quarter. PFG Investments LLC now owns 109,278 shares of the company’s stock valued at $17,287,000 after acquiring an additional 88,707 shares during the last quarter. Finally, Oakworth Capital Inc. grew its position in Johnson & Johnson by 10.8% during the first quarter. Oakworth Capital Inc. now owns 21,780 shares of the company’s stock valued at $3,445,000 after acquiring an additional 2,130 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on JNJ shares. Bank of America reduced their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Raymond James raised their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Finally, Royal Bank of Canada cut their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Trading Down 1.5 %

JNJ stock traded down $2.21 on Tuesday, reaching $144.61. The company’s stock had a trading volume of 8,814,891 shares, compared to its average volume of 7,383,957. The business has a fifty day simple moving average of $154.80 and a two-hundred day simple moving average of $155.14. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The firm has a market cap of $348.48 billion, a PE ratio of 9.02, a PEG ratio of 2.41 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.68 earnings per share. As a group, research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. The ex-dividend date is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 29.68%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.